Abstract: The present invention provides microfluidic pScreen™ devices for quantifying the concentration of DNA fragments in a liquid sample by using magnetic-responsive silica micro-beads and nonmagnetic-responsive silica micro-beads. The devices of the present invention allow for rapid, simple and inexpensive quantification of DNA fragment concentration in a sample. The devices do not require complex instrumentation and can be performed in less than three minutes. Moreover, they are compatible with complex samples including, without limitation, unpurified PCR amplification products, and thus can be expected to seamlessly integrate into various common molecular biology techniques and workflows.

Abstract: The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: Methods for treating malaria are provided, the treatment comprising the step of removing malaria-infected red blood cells from the patient's blood. Blood is drawn from the patient's circulatory system and circulated through a blood purification device that selectively eliminates the infected red blood cells from all other blood's components and replaces the cleansed blood back into the patient's circulatory system. A blood purification device, which is useful to perform the therapeutic methods of the invention, is also provided. The device leverages the magnetic properties of the hemozoin contained within the infected red blood cells and comprises one or more separation chambers (4) though which blood flows through a high-gradient magnetic field generated by an array of wires (5) separated from the chambers and not in contact with the patient blood.

Abstract: The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: Methods for treating malaria are provided, the treatment comprising the step of removing malaria-infected red blood cells from the patient s blood. Blood is drawn from the patient s circulatory system and circulated through a blood purification device that selectively eliminates the infected red blood cells from all other blood s components and replaces the cleansed blood back into the patient s circulatory system. A blood purification device, which is useful to perform the therapeutic methods of the invention, is also provided. The device leverages the magnetic properties of the hemozoin contained within the infected red blood cells and comprises one or more separation chambers (4) though which blood flows through a high-gradient magnetic field generated by an array of wires (5) separated from the chambers and not in contact with the patient blood.

Abstract: A solid polymeric electrolytic membrane comprising a solution of an ion compound in a cross-linked polyether including a liquid plasticizer obtained by:a) copolymerizing a vinyl ether of the formula:R--(O--CH.sub.2 --CH.sub.2 --).sub.n --O--CH=CH.sub.2 (I)with an allyl vinyl ether of the formula:CH.sub.2 =CH--CH.sub.2 --(O--CH.sub.2 --CH.sub.2 --).sub.m --O--CH=CH.sub.

Abstract: Compounds of general formula ##STR1## wherein: R is a linear or branched C.sub.1 -C.sub.20 alkyl radical, m is either 0 or 1; n has a value of from 1 to 10, are corrosion inhibitors, suitable for inhibiting the general corrosion and the stress brittlening caused by hydrogen sulfide (SSC), in an acidic environment, in the presence, or absence of carbon dioxide, of medium-and high-strength manganese steels and low-alloy steels, commonly used in petrochemical facilities and in bore drilling, transport and processing systems for natural gas or petroleum.

Abstract: An amorphous modified poly(2,6-dimethyl-p-oxyphenylene) (PPO) is described with a glass transition temperature (Tg) within the range of 170.degree.-220.degree. C., of which the macromolecules contain units having trialkylsilyl groups bonded to the nucleus and/or to the methyl: ##STR1## together with units having hydroxyethyl groups bonded to the nucleus and/or to the methyl: ##STR2## This modified PPO is prepared by metalating PPO with a metalating agent and reacting the formed metalated PPO with a trialkylsilyl halide and with ehtylene oxide in succession.The use of the thus modified PPO for the preparation of flat, including asymmetric, membranes useful in gas mixture separation processes is described.

Abstract: A process for preparing a modified, amorphous poly-(2,6-dimethyl-p-oxyphenylene) (PPO) comprises:(a) metalating PPO with a metalating agent, and(b) functionalizing such a metalated PPO by reacting the PPO with a trialkylsilyl halide and/or ethylene oxide; and is characterized in that the reaction of metalation is carried out in an inert liquid vehicle which contains PPO in an at least partially suspended solid form, by operating under metalating conditions of gradually adding metalating agent to such a suspension, either continuously or as discrete portions. Depending on the functionalizing agents used, and on the sequence of addition thereof, the process makes it possible to obtain PPO polymers which are modified with trialkyl-silyl, hydroxyethylene and/or ethyleneoxytrialkyl-silyl functional groups. The modified PPO polymers are particularly suitable for preparing flat membranes, including asymmetrical membranes, for the separation of gas mixtures.

Abstract: A modified poly(2,6-dimethyl-p-oxyphenylene) with a glass transition temperature in the range of 180.degree.-220.degree. C. is described in which on the average between 10 and 60% of the macromolecules carry:a) an ##STR1## unit; or b) an ##STR2## unit. Said modified poly(2,6-dimethyl-p-oxyphenylene) is useful as a material in the preparation of flat membranes, in particular asymmetric membrane, for gas separation.

Abstract: Coupling agents of general formula ##STR1## and their use in a method for the termination of living polymers obtained by the anionic polymerization of dienic and/or vinylaromatic monomers.

Abstract: Coupling agents of general formula ##STR1## and their use in a method for the termination of living polymers obtained by the anionic polymerization of dienic and/or vinylaromatic monomers.

Abstract: Coupling agents of general formula ##STR1## and their use in a method for the termination of living polymers obtained by the anionic polymerization of dienic and/or vinylaromatic monomers.

Abstract: Coupling agents of general formula ##STR1## and their use in a method for the termination of living polymers obtained by the anionic polymerization of dienic and/or vinylaromatic monomers.